A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials
Abstract To update the efficacy and safety of different drugs for the treatment of patients with hyperphosphatemia in chronic kidney disease, we conducted a network meta-analysis of 22 therapies for the treatment of uncontrolled hyperphosphatemia in patients with chronic kidney disease (CKD). All ra...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-84942-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594739236438016 |
|---|---|
| author | Congyang Zheng Jia Liu Tao Wang Haiyang Hu Yuanyuan Chen |
| author_facet | Congyang Zheng Jia Liu Tao Wang Haiyang Hu Yuanyuan Chen |
| author_sort | Congyang Zheng |
| collection | DOAJ |
| description | Abstract To update the efficacy and safety of different drugs for the treatment of patients with hyperphosphatemia in chronic kidney disease, we conducted a network meta-analysis of 22 therapies for the treatment of uncontrolled hyperphosphatemia in patients with chronic kidney disease (CKD). All randomized controlled trials on hyperphosphatemia published from January 2013 to November 2023 were searched from CNKI, VIP database, Wanfang database, PubMed, Scopus, and Cochrane databases. Meta-analysis was used to evaluate the serum phosphorus, calcium levels, total effective rate and adverse events of patients with chronic kidney disease (CKD). Data collection and quality evaluation were carried out by three evaluators, RevMan (5.5.3) and Stata (1.3.0). A total of 71 RCTs, and 22 treatment strategies were included in this NMA. The results showed that all treatment strategies were effective in improving patients’ blood phosphorus levels. Among them, SL + CT, CA + CC, SL and TCM had higher overall efficacy, RT, TCM and SL + CT had lower blood phosphorus levels, SL + CT, SL and NAM had lower blood calcium levels, and OAC, CC, NAM and SL had higher safety. Among them, SL + CT seems to be the most recommended treatment strategy. In addition, multidrug combination strategies usually have a higher efficacy and safety profile. |
| format | Article |
| id | doaj-art-0aaff142441d4ed59b7334a471106436 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-0aaff142441d4ed59b7334a4711064362025-01-19T12:20:25ZengNature PortfolioScientific Reports2045-23222025-01-0115111210.1038/s41598-024-84942-8A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trialsCongyang Zheng0Jia Liu1Tao Wang2Haiyang Hu3Yuanyuan Chen4College of Traditional Chinese Medicine, Shandong Second Medical UniversityCollege of Pharmacy, Chengdu University of Traditional Chinese MedicineCollege of Pharmacy, Chengdu University of Traditional Chinese MedicineCollege of Pharmacy, Chengdu University of Traditional Chinese MedicineCollege of Traditional Chinese Medicine, Shandong Second Medical UniversityAbstract To update the efficacy and safety of different drugs for the treatment of patients with hyperphosphatemia in chronic kidney disease, we conducted a network meta-analysis of 22 therapies for the treatment of uncontrolled hyperphosphatemia in patients with chronic kidney disease (CKD). All randomized controlled trials on hyperphosphatemia published from January 2013 to November 2023 were searched from CNKI, VIP database, Wanfang database, PubMed, Scopus, and Cochrane databases. Meta-analysis was used to evaluate the serum phosphorus, calcium levels, total effective rate and adverse events of patients with chronic kidney disease (CKD). Data collection and quality evaluation were carried out by three evaluators, RevMan (5.5.3) and Stata (1.3.0). A total of 71 RCTs, and 22 treatment strategies were included in this NMA. The results showed that all treatment strategies were effective in improving patients’ blood phosphorus levels. Among them, SL + CT, CA + CC, SL and TCM had higher overall efficacy, RT, TCM and SL + CT had lower blood phosphorus levels, SL + CT, SL and NAM had lower blood calcium levels, and OAC, CC, NAM and SL had higher safety. Among them, SL + CT seems to be the most recommended treatment strategy. In addition, multidrug combination strategies usually have a higher efficacy and safety profile.https://doi.org/10.1038/s41598-024-84942-8HyperphosphatemiaChronic kidney diseaseSerum phosphorusSerum calciumAdverse eventsNetwork meta-analysis |
| spellingShingle | Congyang Zheng Jia Liu Tao Wang Haiyang Hu Yuanyuan Chen A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials Scientific Reports Hyperphosphatemia Chronic kidney disease Serum phosphorus Serum calcium Adverse events Network meta-analysis |
| title | A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials |
| title_full | A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials |
| title_fullStr | A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials |
| title_full_unstemmed | A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials |
| title_short | A network meta-analysis of therapies for hyperphosphatemia in CKD based on randomized trials |
| title_sort | network meta analysis of therapies for hyperphosphatemia in ckd based on randomized trials |
| topic | Hyperphosphatemia Chronic kidney disease Serum phosphorus Serum calcium Adverse events Network meta-analysis |
| url | https://doi.org/10.1038/s41598-024-84942-8 |
| work_keys_str_mv | AT congyangzheng anetworkmetaanalysisoftherapiesforhyperphosphatemiainckdbasedonrandomizedtrials AT jialiu anetworkmetaanalysisoftherapiesforhyperphosphatemiainckdbasedonrandomizedtrials AT taowang anetworkmetaanalysisoftherapiesforhyperphosphatemiainckdbasedonrandomizedtrials AT haiyanghu anetworkmetaanalysisoftherapiesforhyperphosphatemiainckdbasedonrandomizedtrials AT yuanyuanchen anetworkmetaanalysisoftherapiesforhyperphosphatemiainckdbasedonrandomizedtrials AT congyangzheng networkmetaanalysisoftherapiesforhyperphosphatemiainckdbasedonrandomizedtrials AT jialiu networkmetaanalysisoftherapiesforhyperphosphatemiainckdbasedonrandomizedtrials AT taowang networkmetaanalysisoftherapiesforhyperphosphatemiainckdbasedonrandomizedtrials AT haiyanghu networkmetaanalysisoftherapiesforhyperphosphatemiainckdbasedonrandomizedtrials AT yuanyuanchen networkmetaanalysisoftherapiesforhyperphosphatemiainckdbasedonrandomizedtrials |